Experienced in X-Linked Retinal Dysplasia

Ulrike Schara

Duisburg, NW, DE 
Experienced in X-Linked Retinal Dysplasia
Duisburg, NW, DE 
OverviewLocationsClinical Research

Overview

Ulrike Schara practices in Duisburg, Germany. Ms. Schara is rated as an Experienced expert by MediFind in the treatment of X-Linked Retinal Dysplasia. Her top areas of expertise are Becker Muscular Dystrophy, Duchenne Muscular Dystrophy, Cramp-Fasciculation Syndrome, Gastrostomy, and Thymectomy.

Her clinical research consists of co-authoring 106 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of X-Linked Retinal Dysplasia.

Gender
Female

Locations

Duisburg, NW, Germany
Other Locations
Essen, NW, Germany
Berlin, BE, Germany
Dresden, SN, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
Enrollment Status: Active_not_recruiting
Publish Date: September 23, 2025
Intervention Type: Drug
Study Drugs: SRP-4045 Exon 45-Skipping Treatment, SRP-4053 Exon 53-Skipping Treatment
Study Phase: Phase 3
Long-Term Observational Study of Translarna Safety and Effectiveness in Usual Care
Long-Term Observational Study of Translarna Safety and Effectiveness in Usual Care
Enrollment Status: Active_not_recruiting
Publish Date: March 14, 2025
A Phase 2, Two-Part, Multiple-Ascending-Dose Study of SRP-5051 for Dose Determination, Then Dose Expansion, in Patients With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment
A Phase 2, Two-Part, Multiple-Ascending-Dose Study of SRP-5051 for Dose Determination, Then Dose Expansion, in Patients With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment
Enrollment Status: Terminated
Publish Date: March 10, 2025
Intervention Type: Drug
Study Drug: SRP-5051 Exon 51-Skipping Treatment
Study Phase: Phase 2
Randomised, Double Blind, Placebo Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy
Randomised, Double Blind, Placebo Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: February 02, 2023
Intervention Type: Drug
Study Drug: Givinostat
Study Phase: Phase 3
Tamoxifen in Duchenne Muscular Dystrophy: A Multicenter, Randomised, Double-blind, Placebo-controlled, Phase 3 Safety and Efficacy 48-week Trial
Tamoxifen in Duchenne Muscular Dystrophy: A Multicenter, Randomised, Double-blind, Placebo-controlled, Phase 3 Safety and Efficacy 48-week Trial
Enrollment Status: Completed
Publish Date: December 20, 2022
Intervention Type: Drug
Study Drug: Tamoxifen
Study Phase: Phase 3
Duchenne Muscular Dystrophy: Double-blind Randomized Trial to Find Optimum Steroid Regimen
Duchenne Muscular Dystrophy: Double-blind Randomized Trial to Find Optimum Steroid Regimen
Enrollment Status: Completed
Publish Date: August 12, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Phase III Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy, Safety and Tolerability of Idebenone in Patients With Duchenne Muscular Dystrophy Receiving Glucocorticoid Steroids
A Phase III Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy, Safety and Tolerability of Idebenone in Patients With Duchenne Muscular Dystrophy Receiving Glucocorticoid Steroids
Enrollment Status: Terminated
Publish Date: December 03, 2021
Intervention Type: Drug
Study Drug: Idebenone
Study Phase: Phase 3
Prospective, Longitudinal Study of the Natural History and Functional Status of Patients With Myotubular Myopathy (MTM)
Prospective, Longitudinal Study of the Natural History and Functional Status of Patients With Myotubular Myopathy (MTM)
Enrollment Status: Completed
Publish Date: June 07, 2018
View 7 Less Clinical Trials

106 Total Publications

Efficacy and safety of gene therapy with onasemnogene abeparvovec in children with spinal muscular atrophy in the D-A-CH-region: a population-based observational study.
Efficacy and safety of gene therapy with onasemnogene abeparvovec in children with spinal muscular atrophy in the D-A-CH-region: a population-based observational study.
Journal: The Lancet regional health. Europe
Published: June 28, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Schara's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 35 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile